Proprietary Multi-Active Artemisia Composition
Prevention & Treatment of Dysplastic Epidermal Cell Growth
Preclinical/Clinical-StageActive
Key Facts
Indication
Prevention & Treatment of Dysplastic Epidermal Cell Growth
Phase
Preclinical/Clinical-Stage
Status
Active
Company
About EpiPharm
EpiPharm AG is a privately held, clinical-stage biotechnology company based in Switzerland, focused on the discovery and development of highly effective, natural treatments for skin disorders. The company's breakthrough platform centers on the therapeutic application of Artemisinin compounds, with a key publication validating artemether for seborrhoeic keratosis. Led by a highly experienced senior pharma executive team, EpiPharm holds therapeutic use patents until 2027/2034 and is actively pursuing partnership opportunities to advance its pipeline targeting dysplastic epidermal cell growth.
View full company profile